结直肠癌患者生活质量缺陷诊断与个体化治疗选择的随机试验
该随机、单盲、多中心试验纳入220例术后原发性结直肠癌患者,比较基于生活质量(QoL)档案(13个QoL量表加特定治疗推荐)的诊疗路径与标准术后照护。
要点
- NNT=7(95%CI 3-225),提示QoL诊疗路径可减少需QoL治疗患者。
- 该试验结果与既往乳腺癌随机对照试验一致,支持将QoL概念纳入指南。
核心结论
- 结直肠癌患者从QoL缺陷诊断和个体化治疗选择中获益。
- 该试验证实了既往乳腺癌随机对照试验的结果。
- QoL概念的实施应成为癌症治疗指南的标准。
研究设计与样本
- 随机、单盲、多中心临床试验,纳入220例术后原发性结直肠癌患者(每组110例)。
- 患者随机1:1接受QoL档案诊疗路径或遵循德国国家结直肠癌指南的标准术后照护。
- QoL采用EORTC QLQ-C30和QLQ-CR29在术后基线及随访3、6、12、18个月测量。
主要发现
- 基线时需QoL治疗比例:干预组92/103(89%),对照组86/104(83%)。
- NNT=7(95%CI 3-225)。
关键数值与推荐
- 干预组QoL档案包含13个QoL量表及特定治疗推荐,转发给患者的协调执业医师。
- 主要终点为术后12个月每组需QoL治疗的患者比例。
- 在意向治疗人群中分析。
临床怎么用
- 在结直肠癌术后照护中,可考虑系统评估QoL缺陷并据此提供个体化治疗选择。
- QoL诊疗路径可能减少术后12个月仍需QoL治疗的患者比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The implementation of quality of life (QoL) concepts in routine care, is still an open matter. We followed the Medical Research Council framework for complex interventions to implement a model of QoL diagnosis and therapeutic options, and investigated its effectiveness in patients with colorectal cancer. METHODS: This randomised, single-blind, multicentre, clinical trial enrolled patients diagnosed with primary colorectal cancer aged 18 years or older who were surgically treated in one of four recruiting hospitals in Germany. All patients received aftercare from one of 178 coordinating practitioners (CPs) who had access to 75 healthcare professionals providing tailored therapies. QoL was measured (EORTC QLQ-C30, QLQ-CR29) in all patients after surgery (baseline) and during aftercare (3, 6, 12, 18 months). Patients were randomised (1:1) into two groups: a care pathway, including QoL-profiles consisting of 13 QoL scales plus specific therapeutic recommendations forwarded to the patient's CP or standard postoperative care adhering to the German national guideline for colorectal cancer (control). The primary endpoint was the proportion of patients in each group with a need for QoL therapy 12 months after surgery. Analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02321813 and closed to accrual. FINDINGS: Between Jan 13, 2014, and Oct 28, 2015, 220 patients were enrolled and randomly assigned (n = 110 per group). At baseline (in hospital after surgery), a need for QoL therapy was diagnosed in 92/103 (89%) of intervention and 86/104 (83%) of control group patients. At 12 months (primary endpoint) the proportion of patients with a need for QoL therapy was 35/83 (42%; 95% CI 31-54%) in the intervention group versus 50/87 (57%; 95% CI: 46-68%) in the control group (p = 0·046, number needed to treat = 7; 95% CI 3-225). INTERPRETATION: Patients profited from the diagnosis of QoL deficits and tailored therapeutic options in their treatment of colorectal cancer. This trial confirmed the results of a previous RCT in breast cancer patients. The implementation of QoL concepts should become standard in treatment guidelines on cancer care. FUNDING: Federal Ministry of Education and Research (BMBF; grant no. 01GY1339). CLINICAL TRIAL INFORMATION: NCT02321813.
引用
- Klinkhammer-Schalke M, Steinger B, Koller M, et al. Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer. Eur J Cancer. 2020. PMID: 32179445. doi:10.1016/j.ejca.2020.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。